Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on BioCryst (BCRX – Research Report) today and set a price target of $11.00.
Tazeen Ahmad’s Buy rating on BioCryst Pharmaceuticals (ticker: BCRX) is primarily based on the promising pipeline opportunities the company has unveiled recently. According to Ahmad, the introduction of five new early-stage programs, with the potential to provide first-in-class or best-in-class therapies across a range of treatments, shows great promise. These programs are expected to yield proof-of-concept (POC) data within the next five years, providing a significant potential for growth.
The management’s expansion of their pipeline portfolio is highly encouraging, especially considering the previous concerns about the long-term opportunities beyond their commercial product, Orladeyo. Ahmad believes that the current stock price undervalues the long-term potential of Orladeyo. Also, the company’s pipeline value has been increased to $1bn from $500mn, indicating a positive outlook for the future. Therefore, Ahmad remains confident with the Buy rating for BioCryst, considering the potential long-term benefits and the current undervaluation of the stock.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $20.00 price target.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
BioCryst (BCRX) Company Description:
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
Read More on BCRX:
- BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®
- BioCryst announces drug discovery updates ahead of R&D day
- BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months
- Clearside to receive $5M upfront in license agreement with BioCryst
- BioCryst price target lowered to $10 from $11 at Jefferies
